Automata, a London, UK-based automation company helping life sciences rapidly innovate, diagnose and discoverat scale, raised US$50m in Series B funding.
The round was led by Octopus Ventures with participation from returning investors Hummingbird, Latitude Ventures, ABB Technology Ventures, Isomer Capital as well as strategic investors such as In-Q-Tel, amongst others.
The company intends to use the funds for development, in the UK and beyond, of Automata Labs for scientists working across diagnostic, drug discovery and biotech.
Led by Mostafa ElSayed, CEO, Automata provides a technology platform that allows life scientists to rapidly innovate, diagnose and discover at scale. Its systems have been utilised by NHS pathology labs to help them meet diagnostic backlogs and upscale capacity, in one of these labs they are running 40 fully automated stations 24/7.
Automata is also currently advising and deploying automation with contract research organisations, research labs and leading blue chip healthcare institutions.
FinSMEs
22/02/2022